IGF-1 LR3

1. Quick Facts

Property	Value
Category	Long-Acting IGF-1 Analog
Risk Level	High
Research Status	Limited Human Research / Moderate Preclinical Research
Administration	Subcutaneous Injection
Typical Frequency	Daily
Estimated Half-Life	Long-Acting (~20–30 Hours Reported)
Primary Research Interest	Muscle Growth / Recovery / Nutrient Partitioning

Important Disclaimer

This material is provided strictly for educational and informational purposes related to peptide research and performance-enhancing compounds. IGF-1 LR3 is a potent biologically active growth factor analog capable of significantly influencing glucose metabolism, cellular growth signaling, tissue development pathways, and endocrine function. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.

2. Summary

IGF-1 LR3 is a modified long-acting analog of insulin-like growth factor-1 (IGF-1) designed to extend biological activity beyond that of native IGF-1. Structural modifications reduce binding to insulin-like growth factor binding proteins and allow prolonged receptor activity compared with endogenous IGF-1.

Research interest in IGF-1 LR3 primarily centers around muscle growth, recovery support, nutrient partitioning, tissue regeneration, and anabolic signaling pathways.

What People Commonly Claim

Rapid increases in lean muscle mass
Enhanced nutrient partitioning
Dramatic recovery improvements
Increased muscle fullness and training pumps
Accelerated injury recovery
Superior anabolic effects compared with HGH
Minimal side effects when properly dosed

What the Literature Actually Shows

Direct LR3 research demonstrates anabolic and growth-signaling activity.
LR3 has demonstrated preservation of lean tissue in experimental models.
Growth-promoting effects extend beyond skeletal muscle and may affect multiple tissues.
Human outcome data remain limited compared with HGH or approved IGF-1 therapies.
Evidence supporting dramatic muscle-growth claims is weaker than commonly portrayed.
Concerns regarding hypoglycemia, abnormal tissue growth, and long-term exposure to elevated IGF signaling remain important considerations.

CKF Transparency Note: IGF-1 LR3 is a modified long-acting analog of insulin-like growth factor-1 designed to extend biological activity beyond that of native IGF-1. Direct research demonstrates anabolic and growth-signaling effects, but the overall evidence base remains substantially smaller than that of Human Growth Hormone or approved IGF-1 therapies. Many claims regarding dramatic muscle gain, nutrient partitioning, and performance enhancement originate from performance-enhancement communities and exceed the strength of available human evidence. Because IGF-1 signaling plays a central role in cellular growth pathways, concerns regarding hypoglycemia, abnormal tissue growth, organ growth, and theoretical cancer-related signaling warrant careful consideration.

3. Reconstitution Guide

Vial Size: 1 mg
Dilutant Type: Dilute Acetic Acid Solution
Amount of Dilutant Added: 2 mL
Final Concentration: 0.50 mg/mL (500 mcg/mL)

At this concentration:
• 20 mcg = 0.040 mL (4.0 units)
• 60 mcg = 0.120 mL (12.0 units)
• 100 mcg = 0.200 mL (20.0 units)

4. Route of Administration

IGF-1 LR3 is most commonly administered as a subcutaneous injectable growth factor analog.

Primary Route: SubQ Injection
Preferred Timing: Variable; timing strategies differ substantially between protocols
Administration Notes: Pre-workout and post-workout timing preferences are commonly discussed, though strong evidence supporting one approach over the other remains limited.

5. Typical Research Protocols

Product Strength: 0.50 mg/mL (500 mcg/mL)
Typical Delivered Amount: 20–60 mcg daily, not to exceed 100 mcg per day
Frequency: Daily
Cycle Length: No standardized research protocol exists; duration recommendations vary widely within performance-enhancement communities
Special Notes: Discussions surrounding IGF-1 LR3 frequently emphasize workout timing, nutrient timing, and recovery support. However, much of this guidance originates from anecdotal experience rather than controlled human research. Conservative dosing is commonly emphasized due to concerns involving hypoglycemia and prolonged exposure to elevated IGF signaling.

6. Mechanism of Action

IGF-1 LR3 functions by activating insulin-like growth factor-1 receptors involved in anabolic signaling, tissue growth, nutrient utilization, cellular repair, and recovery pathways.

IGF-1 receptor activation
Enhanced nutrient partitioning signaling
Satellite cell activation
Protein synthesis signaling
Glucose uptake enhancement
Cellular growth pathway activation
Tissue repair and regeneration signaling

Unlike native IGF-1, LR3 was engineered to remain active for longer periods and demonstrate reduced interaction with certain binding proteins, potentially increasing biological activity and duration.

7. Potential Benefits

Potential lean muscle mass support
Enhanced recovery signaling
Improved nutrient partitioning
Potential training-performance support
Possible tissue-repair enhancement
Potential anabolic signaling support

8. Potential Risks / Side Effects

High

Hypoglycemia
Water retention
Headaches
Dizziness
Fatigue
Abnormal tissue growth concerns
Potential organ growth signaling concerns
Altered insulin sensitivity
Theoretical cancer-signaling concerns

9. Half-Life

IGF-1 LR3 is commonly reported as having an estimated half-life of approximately 20–30 hours, making it substantially longer acting than native IGF-1. The extended duration results from structural modifications that reduce binding to insulin-like growth factor binding proteins and prolong biological activity.

Despite the widespread reporting of this half-life range within research and performance-enhancement communities, published pharmacokinetic data remain limited compared with approved IGF-1 therapies. As a result, precise estimates of circulating activity and tissue-level effects should be interpreted cautiously.

The prolonged activity profile is one of the primary reasons IGF-1 LR3 remains popular in muscle-growth and recovery-focused discussions, as it may provide sustained IGF-1 receptor activation compared with native IGF-1. However, the same extended activity also contributes to concerns regarding hypoglycemia, abnormal tissue growth signaling, and long-term exposure to elevated IGF-related pathways.

10. Storage Information

Store refrigerated before and after reconstitution
Protect from direct light exposure
Avoid repeated freeze-thaw cycles
Maintain sterile handling practices during preparation
Avoid prolonged room-temperature exposure
Discard solutions showing contamination, precipitation, or unexpected discoloration

11. Contraindications / Warnings

Active cancer or cancer history
Diabetes or hypoglycemia disorders
Pregnancy or breastfeeding
Use alongside other potent anabolic growth factors
Known hypersensitivity to peptide compounds
Uncontrolled endocrine disorders
History of abnormal tissue-growth disorders

12. Further Study

Current Evidence Gaps

Long-term human safety outcomes
Long-term cancer-risk outcomes in healthy individuals
Optimal dosing strategies for non-clinical use
Performance-enhancement outcomes in healthy populations
Long-term effects of sustained IGF receptor activation
Comparative outcomes versus HGH and approved IGF-1 therapies
Effects of chronic exposure on glucose regulation and insulin sensitivity

13. Research References

PubMed
PubMed Central (PMC)
NIH Publications
IGF signaling literature
Endocrinology literature
Growth-factor biology literature
Sports medicine and performance physiology literature
Cancer-signaling and tumor-biology literature

14. Last Reviewed

June 2026

IGF-1: 179-90-450